Christopher Rovaldi serves as the Chief Operating Officer at Keros Therapeutics Inc., a biopharmaceutical company focused on developing transformative treatments for hematological and musculoskeletal disorders. With a robust background in the biopharmaceutical industry, Rovaldi brings extensive experience in operations, strategic planning, and business development to his role. Prior to joining Keros Therapeutics, he held several high-level positions at leading companies, including serving as the Chief Operating Officer at Achillion Pharmaceuticals, where he played a pivotal role in advancing the company's strategic initiatives and operational capabilities. At Keros Therapeutics, Rovaldi is instrumental in overseeing the company's day-to-day operations and ensuring the seamless execution of its clinical and research programs. His strategic vision and leadership have been crucial in driving the company's growth and development, particularly in advancing its pipeline of innovative therapies. Under his guidance, Keros Therapeutics has made significant strides in progressing its lead candidates through various stages of clinical trials, bringing the company closer to its goal of delivering life-changing treatments to patients. Rovaldi's achievements in the biopharmaceutical sector are marked by his ability to navigate complex regulatory landscapes and foster collaborative relationships with key stakeholders. His expertise in operational management and strategic planning has not only strengthened Keros Therapeutics' position in the market but also enhanced its capacity to innovate and deliver on its mission. As the Chief Operating Officer, Rovaldi continues to lead with a focus on excellence and a commitment to improving patient outcomes, solidifying his reputation as a respected leader in the industry.